Moderna, Inc.: Moderna and Merck Announce mRNA-4157 in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA aloneThe DMFS results

Related Keywords

Canada ,United States ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Kyle Holen ,Peter Dannenbaum ,Colleen Hussey ,Julie Cunningham ,Stefan Klotter ,Lavina Talukdar ,Erich Rubin ,Damini Chokshi ,Youtube ,Statement Of Merck Co Inc ,Drug Administration ,Brand Corporate Affairs ,American Association For Cancer Research ,American Society Of Clinical Oncology ,Moderna Inc View ,Merck Research Laboratories ,Eastern Cooperative Oncology Group ,Exchange Commission ,Linkedin ,Instagram ,Facebook ,Head Of Development ,European Medicines Agency ,Moderna Inc ,Nasdaq ,Merck Co Inc ,Twitter ,Clinical Oncology ,Annual Meeting ,Senior Vice President ,Merck Research ,Breakthrough Therapy Designation ,Priority Medicines ,American Association ,Cancer Research ,Performance Status ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Connective Tissue ,Patients With Multiple ,Neck Squamous Cell ,Bacillus Calmette Guerin ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Looking Statement ,Securities Litigation Reform Act ,Annual Report ,Private Securities Litigation Reform Act ,Prescribing Information ,Medication Guide ,Media Contacts ,Investor Contacts ,Vice President ,Inc View ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,Moderna ,Merck ,Nnounce ,Rna ,157 ,Combination ,Ith ,Keytruda ,Remonstrated ,Statistically ,Significant ,Linically ,Meaningful ,Improvement ,Distant ,Metastasis ,Tree ,Survival ,Patients ,Thigh ,Risk ,